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Background: Down syndrome (DS), caused by an extra copy of chromosome 21, affects 1 in 750 live births and is
characterized by cognitive impairment and a constellation of congenital defects. Currently, little is known about the
molecular pathogenesis and no direct genotype-phenotype relationship has yet been confirmed. Since DS
amniocytes are expected to have a distinct biological behaviour compared to normal amniocytes, we hypothesize
that relative quantification of proteins produced from trisomy and euploid (chromosomally normal) amniocytes will
reveal dysregulated molecular pathways.
Results: Chromosomally normal- and Trisomy 21-amniocytes were quantitatively analyzed by using Stable Isotope
Labeling of Amino acids in Cell culture and tandem mass spectrometry. A total of 4919 unique proteins were
identified from the supernatant and cell lysate proteome. More specifically, 4548 unique proteins were identified
from the lysate, and 91% of these proteins were quantified based on MS/MS spectra ratios of peptides containing
isotope-labeled amino acids. A total of 904 proteins showed significant differential expression and were involved in
25 molecular pathways, each containing a minimum of 16 proteins. Sixty of these proteins consistently showed
aberrant expression from trisomy 21 affected amniocytes, indicating their potential role in DS pathogenesis. Nine
proteins were analyzed with a multiplex selected reaction monitoring assay in an independent set of Trisomy
21-amniocyte samples and two of them (SOD1 and NES) showed a consistent differential expression.
Conclusions: The most extensive proteome of amniocytes and amniotic fluid has been generated and differentially
expressed proteins from amniocytes with Trisomy 21 revealed molecular pathways that seem to be most
significantly affected by the presence of an extra copy of chromosome 21.
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Down syndrome (DS) presents with a constellation of
symptoms that are attributed to complete or partial trip-
lication of human chromosome 21. Trisomy 21 (T21) is
the most common human chromosomal anomaly, affect-
ing approximately 1 in 750 live births in North America.
The range and severity of phenotypic features of DS vary
from individual to individual. For example, cognitive* Correspondence: ediamandis@mtsinai.on.ca
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reproduction in any medium, provided the orimpairment is nearly universal among the DS-affected
individuals, whereas congenital heart diseases are found
in approximately 40 to 50% of them. Despite the high
prevalence of DS and early identification of the cause
(T21), its molecular pathogenesis has been poorly under-
stood and specific treatments have consequently been
practically unavailable.
Pregnancy progression and fetal development involve
complex feto-maternal physiological processes that rely
on intricate interactions of multitudes of genes and pro-
teins. Therefore, the balance among these interactions
will be compromised at more than one level when a
major disturbance occurs. Large-scale investigations to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cused on the mRNA level, which aimed to compare gene
expression levels between the chromosomally normal
(CN) and T21 status. A number of genes that showed
over- or under-expression in these studies have been
proposed to be responsible for DS phenotypes: APP,
BACH1, TIAM1, SOD1, SYNJ1, OLIG1, OLIG2, IFNAR1,
IFNAR2, IFNGR2, GART, ITSN1, DSCR1, CBR1, CBR3,
DOPEY2, MORC3, CLDN14, SIM2, HLCS, PIGP, TTC3,
DSCR3, DYRK1A, KCNJ6, ERG, Ets2, HMGN1, PCP4,
DSCAM, BACE2, and S100β [1-5]. A major disturbance
such as an extra copy of chromosome is subsequently
reflected at the level of protein production and expres-
sion, and as the end-players that constitute the func-
tional units of genes; proteins are of great value to
analyze, in order to elucidate altered molecular path-
ways. We therefore hypothesized that identification of
proteins that are involved in altered biochemical path-
ways, via quantitative analysis of the amniocyte prote-
ome, will provide insights into the causes of DS
phenotypes.
Amniotic fluid can be divided into two major compo-
nents: supernatant fluid and free-floating fetal cells
called amniocytes (also known as amniotic fluid cells).
The proteome of the supernatant fluid has been actively
studied, in pursuit of biomarker discovery for various
prenatal conditions, including DS [6-8]. However, the
proteome of the supernatant fluid poorly reflects intra-
cellular or molecular processes, because the intracellular
proteome of fetal tissue is inadequately represented.
Amniocytes are shed from all three germ layers of the
fetus, and some of these cells that originate from embry-
onic and extra-embryonic tissues show stem cell-like
properties, enabling prolonged culture [9,10]. Although
amniocytes have long been used for routine prenatal diag-
nosis for a variety of fetal abnormalities, characterization
of the types and properties of cells that exist in amniotic
fluid has not yet been completed [10]. Initial classifi-
cation of amniotic fluid cells was reported in the
1980s, grouping them into epithelioid, amniotic fluid-
specific and fibroblastoid types, based on their mor-
phological and growth characteristics [11]. Recently,
amniocytes are recognized as a rich source for pluri-
potent stem cells which may be useful for therapeutic
purposes. In one study, human and rodent amniotic
fluid cells expressing stem cell markers were isolated,
and were successfully induced with growth factors to
differentiate into adipogenic, myogenic, osteogenic,
neuronal, endothelial, and hepatic lineages [12].
Since amniocytes with T21 are expected to have a dis-
tinct biological behavior from CN amniocytes, we
hypothesize that relative mass spectrometry-based quan-
tification and comparison of proteins produced from tri-
somy and euploid amniocytes will reveal dysregulatedmolecular pathways. To elucidate the affected pathways
and networks, we used stable isotope labeling with
amino acids in cell culture (SILAC) to perform an un-
biased relative quantitation of amniocyte proteins.
SILAC offers global quantitation with high labelling effi-
ciency with minimal sample manipulation and technical
variations. In the second part of the present study, can-
didate proteins were selected based on the quantitative
analysis, to represent the potentially dysregulated net-
works in amniocytes with T21. The final part involved
verification of the candidates via developing selected re-
action monitoring (SRM) assays to quantitatively assess
the differential expression in individual amniocyte sam-
ples, obtained at various gestational weeks in the second
trimester.
Results
Optimization of amniocyte culture and labelling
Our preliminary experiments showed that there were no
significant morphologic differences between CN and
T21 amniocyte cultures up to approximately 8 doubling
times, beyond which point T21 amniocytes failed to
thrive. All SILAC-labeled cells were harvested after a
minimum of 5 doubling times. One confluent T-175
(17,500 mm2 surface area) flask contained approximately
5 × 106 cells, which yielded approximately 1 mg of
secreted proteins. Amniocytes were grown in serum-free
media (without AmnioMax Supplement and fetal bovine
serum) for 48 hours before harvest, to ensure that the
harvested cells are not contaminated by exogenous pro-
teins. The incubation period of 48 hours in the serum-
free media was optimized to maximize secreted protein
concentration while minimizing cell death.
Identification and quantification of proteins by mass
spectrometry
To account for biovariability, we created a “control” pair,
which consists of a mixture of equal amount of proteins
from two separate amniocyte cultures originating from
two different individuals of the same gestational age
(both cytogenetically normal; CN:CN pair). A total of
three “experimental” pairs were created similarly, by
combining equal amounts of T21 amniocytes and CN
amniocytes matched for gestational week (CN:T21
pairs). A total of 4919 unique proteins were identified
from the amniotic fluid cell proteome (lysate and super-
natant) at the false positive rate of 1% at both the pep-
tide and protein level (Figure 1A). More specifically,
4548 unique proteins were identified from the lysate,
and 91% of these proteins were quantified using Max-
Quant (Additional file 1). From the supernatant (amnio-
cyte conditioned media), 2459 unique proteins were
identified (Additional file 2). Out of 4548 identified pro-
teins from the lysate, 3200 of them were common
Figure 1 The amniocyte proteome. (A) A total of 4919 unique proteins were identified from supernatant and lysate of amniotic fluid cells.
(B) Amniocyte lysate proteome: a total of 4548 proteins were identified from four pairs of amniocyte lysate (control pair and experimental pairs 1–
3). The control pair consisted of “heavy” labeled amniocytes obtained from one euploid fetus and “light” labeled amniocytes from another
euploid fetus. Each experimental pair consisted of “heavy” labeled amniocytes obtained from fetus with T21 and “light” labeled amniocytes
obtained from euploid fetus. (C) Amniocyte lysate proteome of each individual experimental pair: a total of 4023 proteins were identified in
these pairs.
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(Figure 1B). Moreover, out of 4023 proteins identified in
the experimental pairs from the lysates, 2515 were found
in the three pairs and 2976 in two of them (Figure 1C).
Similar results were found in the supernatants. MS
proteomics data have been submitted to the ProteomeX-
change consortium (submission reference: 1-20130129-
76233).
Quantitative analysis to identify aberrantly expressed
proteins in lysates
MaxQuant generates the ratios between “heavy”-labelled
versus “light”-labelled proteins based on razor peptides,
and normalizes the ratios so that the median of the loga-
rithms of peptide ratios would be equal to zero. We thus
obtained the normalized ratios and plotted proteins with
statistically significant ratio values, to observe fold
changes. This fold-change analysis of the lysate prote-
ome (n = 4548) revealed that a total of 3593 proteins
showed statistically significant “heavy” to “light” ratios.
The mean normalized ratio was 0.91, with the vast ma-
jority of proteins showing less than two-fold increase or
decrease, signifying little difference in the expression of
the majority of proteins between the CN and T21
conditions.
Rather than applying an arbitrary cut-off value for
fold-changes, two standard deviations from the control
pair (CN:CN) was applied to the list of proteins of eachexperimental pair (CN:T21) to identify proteins with po-
tentially significant differential expression. After remov-
ing the proteins that showed significant differential
expression (outside of two standards of deviation) for
the control pair (CN:CN), as well as reverse hits and
contaminants, a total of 1135 proteins constituted the
initial list of candidates. The next step was designed to
maximize the number of proteins that show a true dif-
ference, with the least number of false-positives. We
removed proteins that showed inconsistent fold-change
between different biological replicates, based on a few
razor peptides, and 904 proteins remained. The top mo-
lecular and cellular functions of these 904 proteins are
represented in Additional files 3 and 4. Finally, these 904
proteins were manually checked for consistency between
the ratios for different peptides of each protein, as well
as for consistency in the pattern of expression of experi-
mental pairs, and only those that show consistency with
both criteria were retained. Sixty proteins, called “high
probability” proteins, showed a significantly decreased
(n = 29) or increased (n = 31) expression in T21 amnio-
cytes (Tables 1 and 2).
Construction of networks using bioinformatic databases
Using the Ingenuity Pathway Analysis (IPA) software, we
analyzed the list of 904 proteins to identify molecular
pathways that may be directly affected due to the identi-
fied expression changes. A total of 25 pathways were
Table 1 Proteins that show decreased expression in T21 amniocytes (n = 29)
Gene name Protein name Ratio (H/L)1
AKAP12 A-kinase anchor protein 12 0.41
APOA1 Apolipoprotein A-I 0.07
APOC3 Apolipoprotein C-III variant 1 0.12
ARHGEF2 Rho guanine nucleotide exchange factor 2 0.52
CNBP cDNA FLJ77718 0.42
CTRB1 cDNA FLJ77335, highly similar to Homo sapiens chymotrypsinogen B1 (CTRB1), mRNA 0.12
ERC1 ELKS/RAB6-interacting/CAST family member 1 0.63
FBLIM1 Filamin-binding LIM protein 1 0.62
FHL3 Four and a half LIM domains protein 3 0.59
HMGA2 HMGA2e 0.52
HPX Hemopexin 0.22
ICAM1 Intercellular adhesion molecule 1 0.62
IGF2R Cation-independent mannose-6-phosphate receptor 0.65
LTF Lactotransferrin 0.05
MARCKSL1 MARCKS-related protein 0.58
MCAM Cell surface glycoprotein MUC18 0.45
NES NES protein 0.18
NUBP1 Nucleotide-binding protein 1 0.30
PCK2 cDNA FLJ50710, highly similar to Phosphoenolpyruvate carboxykinase (GTP), mitochondrial (EC 4.1.1.32) 0.57
PGPEP1 Pyroglutamyl-peptidase 1 0.65
POSTN Periostin 0.25
PPIF Peptidyl-prolyl cis-trans isomerase, mitochondrial 0.20
PZP Pregnancy zone protein 0.11
SDCBP Syndecan binding protein (Syntenin) 0.46
SLC2A1 Solute carrier family 2, facilitated glucose transporter member 1 0.52
SOLO Protein SOLO 0.39
TAF15 TATA-binding protein-associated factor 2N 0.39
TNS1 Tensin-1 0.57
TRIP6 Thyroid receptor-interacting protein 6 0.64
1. Heavy/light ratio with SILAC method, calculated as the average of three experimental pairs when available. Only proteins which showed decreased ratio for
different peptides, as well as consistency in the pattern of expression of experimental pairs were selected.
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from the 904 protein list. Some of the functions and
pathways include: cell morphology, hematological system
development, humoral immune response, lipid metabol-
ism, organismal development, cardiovascular disease,
genetic disorder, metabolic disease, protein degradation,
embryonic development, cancer, neurological disease
and tissue development. The top three pathways with
the highest scores (highest number of proteins that con-
stitute the pathway being represented in the list of 904
proteins) are shown in Figure 2. Ingenuity Pathway Ana-
lysis also identified diseases and disorders, molecular
and cellular functions, and physiological system develop-
ment and functions for the 904 proteins. The top 5 dis-
orders associated with these proteins were: cancer,genetic disorder, neurological disease, skeletal and mus-
cular disorders, and cardiovascular disease. The top 5
molecular and cellular functions included: cellular move-
ment, cell-to-cell signaling and interaction, cell death,
lipid metabolism, and molecular transport. The top 5
physiological system development and functions included:
tissue development, skeletal and muscular system devel-
opment, cardiovascular system development and function,
organismal development, and hematological system
development.
Selection and verification of candidates by SRM
From the list of “high probability” proteins (Table 1 and
Table 2), candidates for further verification via multi-
plexed SRM assay were selected based on a number of
Table 2 Proteins that show increased expression in T21 amniocytes (n = 31)
Gene name Protein name Ratio (H/L)1
AK6 Adenylate kinase isoenzyme 6 2.70
AMIGO2 Amphoterin-induced protein 2 8.92
ARSA Arylsulfatase A 1.71
CD9 CD9 antigen 2.48
CNN3 Calponin-3 1.82
COL8A1 Collagen alpha-1(VIII) chain 1.93
CPA4 Carboxypeptidase A4 4.84
CRYAB Alpha-crystallin B chain 2.70
CTSZ Cathepsin Z 1.96
DDAH1 N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 2.50
DNPEP Aspartyl aminopeptidase 6.19
DPP7 Dipeptidyl-peptidase 2 2.31
GREM1 Gremlin-1 2.78
LCRMP Collapsin response mediator protein 4 long variant 4.38
LPCAT2 Lysophosphatidylcholine acyltransferase 2 2.51
MFI2 Melanotransferrin 2.91
MYH10 Myosin-10 2.47
NAAA N-acylethanolamine-hydrolyzing acid amidase 2.83
NAGLU Alpha-N-acetylglucosaminidase 1.73
P4HA1 Prolyl 4-hydroxylase subunit alpha-1 1.98
PFKL 6-phosphofructokinase, liver type 1.98
PLOD2 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 7.77
PPME1 Protein phosphatase methylesterase 1 1.82
PYGL Glycogen phosphorylase, liver form 1.81
S100A10 Protein S100-A10 2.34
SFXN1 Sideroflexin-1 1.71
SIAE Sialate O-acetylesterase 1.87
SLC25A4 ADP/ATP translocase 1 2.24
SOD1 Superoxide dismutase [Cu-Zn] 1.91
TPM2 Tropomyosin beta chain 2.70
UAP1 UDP-N-acetylhexosamine pyrophosphorylase 1.96
1. Heavy/light ratio with SILAC method, calculated as the average of three experimental pairs when available. Only proteins which showed increased ratio for
different peptides, as well as consistency in the pattern of expression of experimental pairs were selected.
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abundance in amniocytes in order to be robustly and re-
producibly identified by SRM assays. Second, proteins that
showed greater than two-fold difference between “heavy”
and “light” conditions were preferred. Third, proteins
must contain unique proteotypic peptide sequences to
avoid ambiguity. Finally, proteotypic peptides must meet
certain requirements to facilitate selective and sensitive
SRM analysis (see Methods). As a result, nine proteins
were selected for multiplexed SRM assays: AKAP12,
IGF2R, LCRMP, MCAM, NES, PLOD2, PYGL, SOD1 and
TPM2. Ten peptides representing seven housekeeping
proteins were included in the SRM assay as secondaryinternal standards: GAPDH, RPL27A, RPS3, TALDO1,
TUBB, TUBB2C and UBB. The average H:L ratio of these
housekeeping proteins from the SILAC results was 1.02
(Additional file 5). We used correlation of LC retention
time between discovery and SRM gradients to confirm the
identity of selected peptides, as described in more detail
elsewhere [13]. More detailed peptide information, para-
meters of our SRM method, raw values, and coefficients
of variation (CVs) can be found in Additional files 6, 7, 8,
9, 10, 11.
Two of these nine proteins, NES and SOD1, showed a
highly significant differential expression (p < 0.001) in four
out of five amniocyte pairs (Table 3). SOD1 expression was
Figure 2 Top three networks that are potentially disrupted in amniocytes affected with Down syndrome. (A) A network containing 34
associated proteins, 28 of which were identified in our list of 904 proteins. This network is involved in infection mechanism, cellular assembly and
organization, and cardiovascular diseases. (B) A network containing 35 associated proteins, 30 of which were identified in our list of 904 proteins.
This network is involved in cell morphology, hematological system development and function, and humoral immune response. (C) A network
with 35 associated proteins, 29 of which were identified in our list of 904 proteins. This network is involved in cellular assembly and organization,
lipid metabolism, and organismal development.
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showed marked decrease in expression.
Discussion
With the advent of mass spectrometry and bioinformatic
platforms, high-throughput proteomic studies for differ-
ent tissues, under various differentiation stages ordisease conditions, have proliferated in the literature.
Among a few quantitative proteomic techniques, SILAC
has recently gained popularity for global-scale analysis of
proteins in different cell conditions [14]. One notable
advantage of this metabolic labelling technique is that
nearly all peptides of all proteins can contribute to quan-
tification, unlike other labelling techniques that target a
Table 3 Comparison of T21/CN ratios between SILAC and
SRM analysis from a total of 8 experimental pairs (3 pairs
for SILAC and 5 pairs for SRM experiments)
Gene T21/CN ratios according to gestational age (weeks)
Name 15.1 15.5 15.9 16.3 16.4 17.3 18.6 21.5
NES 0.79* 0.19 0.34* 0.31* 0.17 1.26 0.67* N/A
SOD1 1.54* 1.98 1.85* 1.46* 1.74 1.75* 1.16 2.02
T21, Trisomy 21; CN, chromosomally normal; N/A: Not available.
Bolded: Ratios (T21/CN) from SRM analysis.
Italicized: Ratios (T21/CN) from SILAC analysis.
*Statistically significant ratios at p < 0.001, according to Student’s t-test when
the six replicates where compared.
Only the results of two proteins with highly significant fold-change in four out
of five sample pairs (SRM) are displayed.
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belled. We hence utilized SILAC to identify differences
in the proteome of amniotic fluid cells from T21-
affected versus CN fetuses, to identify molecular path-
ways that are responsible for DS pathogenesis.
The next major step after a large-scale discovery phase
is selection of the most promising candidates and verifi-
cation in individual samples by more elaborate quantifi-
cation methods. Our initial filtering criteria for selecting
candidates were based on differences between the con-
trol pair (CN:CN) and the experimental pairs (T21:CN).
For example, when we considered proteins with differ-
ences exceeding 3 standard deviation in H/L ratios, the
control pair showed 38 proteins, whereas the experimen-
tal pairs showed 150 to 300 proteins. These findings sug-
gest that a large number of amniocyte proteins are
expressed in different amounts between the CN and T21
conditions.
There are at least two reasons as to why our quantifi-
cation based on SILAC may potentially have a relatively
large variability. First, amniocytes in primary culture do
not represent a homogenous population, unlike most
other cell cultures. It has been observed previously, as
well as in the current study, that only a subset of amnio-
cytes survive after a few doubling times and the amnio-
cyte cultures become relatively homogeneous, although
the exact nature of these cells are yet to be determined
[10]. Second, the amniocytes used in this study origi-
nated from different individuals. Therefore, the results
were expected to be significantly more variable, com-
pared to studies that use immortalized cells from one in-
dividual. Given that proteins that show differential
expression in only one experimental pair may be due to
analytical variability, only proteins that showed differen-
tial expression across two or more experimental pairs
from our initial list of 904 proteins were retained for fur-
ther analysis. Here, we employed SRM assay for verifica-
tion of SILAC data, since we have previously validatedits accuracy and effectiveness for verification of candi-
dates in amniotic fluid [15].
Network modeling suggested that a number of path-
ways include multiple proteins that are found in our list
of dysregulated proteins (Figure 2). For example, a path-
way that includes NF-κB was one of our top 3 pathways,
and NF-κB, along with NFATc, has been implicated in
the dysregulation of DS candidate region-1 [16,17]. An-
other pathway that includes APP was one of our top 3
pathways, and 29 out of the 35 involved proteins of this
particular network were identified in our list of 904 pro-
teins that seem to be dysregulated. APP gene encodes a
transmembrane protein called amyloid precursor protein
in humans, which can be sequentially cleaved by the ac-
tion of the β and γ secretases, to produce amyloid-beta
(Aβ) peptides. APP protein and its peptides seem to con-
tribute to the pathogenesis of DS by both gain of toxic
functions and loss of normal biological functions. Aβ42
peptide is the main constituent of amyloid plaques that
are a hallmark of Alzheimer’s disease, and recent studies
have suggested that the cognitive decline in Alzheimer’s
is mediated by reduction of synaptic plasticity attributed
to the Aβ plaque formation [18]. Aβ peptides can also
cause cerebral amyloid angiopathy, as these peptides ag-
gregate to coat cerebral blood vessels. Plaques indicating
amyloid angiopathy have also been observed in DS-
affected brains [19]. Although the exact function of APP
is unknown, APP seems to play an important role in dif-
ferentiation or migration processes of neural stem cells.
In vitro studies have shown that APP is required for dif-
ferentiation of neural stem cells, and in vivo, it was
shown that neural stem cells cannot migrate or differen-
tiate in an APP-knockout mouse [20]. Our previous
study showed that APP expression in amniotic fluid is
increased by two-fold in DS-affected pregnancy, as early
as the 16th week of gestation [6]. Based on these previ-
ous and our current findings, we can hypothesize that
APP metabolism is altered at an early stage of fetal de-
velopment, and its degree of alteration may be one of
the most significant, among numerous molecular path-
ways that are implicated in the development of DS
phenotypes.
Several of the candidate proteins have also been dir-
ectly or indirectly associated with various symptoms of
DS in previous studies. The results obtained for SOD1
and NES seem to be particularly consistent. The SOD1
gene is located on chromosome 21 and it encodes for
superoxide dismutase, a ubiquitous protein that is
involved in the clearance of free radicals produced
within cells. Two types of neural pathologies are asso-
ciated with this protein. First, pathogenic variants of this
protein are prone to proteosomal degradation by ubiqui-
tination processes, and such defects have been asso-
ciated with amyotrophic lateral sclerosis type 1 (ALS1), a
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motor neurons [21]. Secondly, SOD1 proteins, both
wild-type and variants, have a tendency to form fibrillar
aggregates, and these aggregates have cytotoxic effects,
resulting in neurodegeneration. Increases in SOD1 and
APP were studied together, and only when combined,
the double transgenic mice showed severe morpho-
logical damage [22]. Our results showed that SOD1, un-
like other candidates, was consistently upregulated in
T21-amniocytes compared to the controls, and this find-
ing supports the traditional gene-dosage hypothesis even
at the protein level. The hypothesis predicts increased
expression of genes encoded in chromosome 21 [23],
and previous studies at the mRNA level have showed
mostly supportive results [24-26].
Unlike SOD1, there is little information available for
NES. This protein seems to be down-regulated accord-
ing to the results of the present study. NES is an inter-
mediate filament protein that has been associated with
Creutzfeldt-Jakob syndrome and pathologic neovascular-
ization. It is expressed in various parts of the human
body, including brain, eyes, ovaries, skin, and some
pathologic tissues such as glioblastoma. NES expression
is also strongly observed in stem cells of the central
nervous system in the neural tube, and it has been
speculated that it has an important role in central ner-
vous system development [27]. Upon terminal neural
differentiation, NES is downregulated and replaced by
neurofilaments.
Although bioinformatic databases allow easy annota-
tion of candidates for their function, tissue expression,
and potentially involved pathways, understanding of
their function must be done within the context of the
cell type and state of the cells. Since amniocytes repre-
sent a relatively heterogeneous population that has not
been fully characterized, speculating on each protein
function in the amniotic fluid cell proteome should be
approached with caution. For example, there may be an
array of proteins that have been well-described in fully
differentiated cells, although the same proteins may be
actively involved in development and/or cellular differ-
entiation during fetal growth. Therefore, information on
their developmental functions from bioinformatic re-
positories may be very limited. Also, expression of pro-
teins in terminally differentiated cells can be quite
different from expression in stem cell-like cells. More-
over, gene dosage clearly depends on the biological func-
tion of the product of the gene, including enzymes,
structural proteins, transcription factors, intracellular
signaling molecules, cell surface markers, and receptors.
There are a few limitations of this study, which origin-
ate from the nature of the samples. For example, the
heterogenous nature of amniotic fluid cells can intro-
duce false-positives into our list of proteins that reflectDS pathogenesis, warranting a verification step. Also, the
heterogeneity of the disease phenotypes and the degree
of severity make the analyses more difficult. For ex-
ample, 50 to 60% of DS individuals suffer from congeni-
tal cardiac defects, and some of the altered pathways for
heart development could or could not be captured in
our candidate list, since not all DS fetuses are affected.
Even for the universal phenotypes, such as cognitive de-
velopment, there is a wide range of severity; therefore
“signature proteins” for any of the phenotypes could po-
tentially be missing from our list, especially at such an
early stage of development.Conclusions
In summary, this study identified over 4,900 proteins
from primary amniocytes via proteomic discovery
experiments, providing the most extensive proteome
data for amniocytes, while quantifying over 85% of the
identified proteins via the SILAC technique. Quantitative
analysis showed that at least 900 proteins were poten-
tially dysregulated in amniocytes with T21. The bioinfor-
matic molecular analyses revealed multiple pathways
that seem to be most significantly affected by the pres-
ence of an extra copy of chromosome 21. Further inves-
tigations of these pathways in fetal tissue may help
elucidate molecular mechanisms that are directly re-
sponsible for DS features. We also designed targeted
SRM assays for candidate verification and identified two
proteins (SOD1 and NES) that could be involved in the
molecular pathogenesis of DS during fetal development.Methods
Amniotic fluid cell culture
A total of three T21 and five CN amniocyte samples
were collected by amniocentesis from women at 15 to
21 weeks of gestation, undergoing prenatal diagnosis.
These amniotic fluid cells were a fraction of the cells
obtained for cytogenetic analysis, and they were grown
to confluency in T-12.5 cm2 flasks for approximate 10 to
14 days in 50% (v/v) AmnioMax C100 combined media
(17% AmnioMax C100 Supplement, 83% AmnioMax
C100 Basal media) and 50% Chang Medium D, at the
Cytogenetics Laboratory of Mount Sinai Hospital. Once
chromosomal status (e.g. CN or T21) was confirmed
and each flask was confluent, we harvested approxi-
mately 50% of these cells as the initial population for
SILAC and placed them in new T-12.5 cm2 flasks. Cells
from an individual constituted a single sample without
pooling at any step, except for 1:1 mix (light/heavy) for
SILAC analysis.
The study protocol was approved by the Institutional
Review Board of Mount Sinai Hospital. Informed
consent was obtained from all participants. The study
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Helsinki Principles.
Stable Isotope Labelling by Amino acids in Cell culture
(SILAC) Media Composition
SILAC media were prepared from customized Dulbeco’s
Modified Eagle’s Medium (DMEM) devoid in two essen-
tial amino acids: L-arginine and L-lysine (AthenaES).
Heavy amino acids, L-Arg6 (13C) and L-Lys8 (13C and
15N), were supplemented to the medium at a concentra-
tion of 72 mg/L and 90 mg/L, respectively, for the
“heavy” medium (Cambridge Isotope Laboratories). For
the control medium (non-heavy or “light”), amino acids
L-arginine and L-lysine were supplemented at a final
concentration of 69 mg/L and 85 mg/L each (Sigma).
Both heavy and light medium were supplemented with
L-proline at a concentration of 150 mg/L (Sigma). All
amino acids were reconstituted in phosphate-buffered
saline (PBS) and were filtered through a 0.22-μm filter
to obtain a sterile solution (Millipore). Additionally, 10%
of dialyzed FBS (Gibco) and AmnioMAX™-C100 Sup-
plement (Gibco) were added to both heavy and light
medium, except for the last 48 hours. “Heavy” medium
was used to incubate T21 amniocytes, and “light”
medium was used to culture CN amniocytes. A mini-
mum of five doubling times was ensured by culturing
cells from half a flask of 12 cm2-surface area to a flask of
175 cm2-surface area at 37°C. Growth media were
replaced with fresh media every two to three days over a
period of approximately 12 days. When cells become >
90% confluent in a T-175 flask, cells were rinsed with
PBS solution three times, and then fresh heavy or light
SILAC media were added to the flasks without FBS or
AmnioMAX™-C100 Supplement. After 48 hours of incu-
bation, both cells and the supernatant were collected
and stored at −20°C until use. Cells were harvested with
trypsin and washed with PBS before centrifugation. Cells
from preliminary experiments were tested for incorpor-
ation of the label after five doubling times.
Cell lysis protocol for proteomic analysis
Amniotic fluid cell supernatants were lyophilized, pre-
ceded by dialysis in 1mM ammonium bicarbonate with
two buffer exchanges, using a molecular cutoff of
3.5kDa, for 24h. Amniotic fluid cells were subjected to
lysis using cold lysis buffer containing 150 mM NaCl, 20
mM Tris, 6 mM CHAPS, and 1 mM PMSF. Cell pellets
were resuspended in 1mM lysis buffer on ice for 10 min-
utes and sonicated using a probe sonicator for 30 sec-
onds (three times, 10 seconds each). Next, samples were
centrifuged at 14000×g for 20 minutes to clear the lysate
and only the supernatant portions were retained. The
lyophilized supernatant proteins were reconstituted in
50 mM sodium bicarbonate. Coomassie total proteinassay (Pierce, USA) was performed to measure total pro-
tein amount in all the supernatant and the lysate sam-
ples, while each sample was measured in triplicate.
Equal amount of “heavy”- and “light”-labelled proteins
were combined in 1:1 ratio, and the combined samples
were lyophilized to dryness.Sample preparation, fractionation, and tandem mass
spectrometry
Lyophilized protein samples were reduced in 372 μL of
solution, containing 322 μL of 8M urea, 25 μL of water
and 25 μL of 200mM DTT at 50°C for 30 minutes. Sam-
ples were subjected to acetylation by 500mM iodoaceta-
mide for an hour, and were desalted on a NAP5 column
(GE Healthcare). After lyophilization, samples were
reconstituted in trypsin solution (1:20, trypsin: protein
concentration; 120 μL of 50 mM ammonium bicarbon-
ate; 100 μL methanol; 150 μL dH2O) and incubated at
37°C overnight (Promega, sequencing grade modified
trypsin).
The detailed description of the sample preparation
procedure for 2D-LC-MS/MS can be found in our previ-
ous paper [8]. Briefly, the digested peptides, in 120 μL of
0.26 M formic acid in 10% ACN (mobile phase A), were
directly loaded onto a PolySULFOETHYL A column.
Fractionation was performed using an Agilent 1100
HPLC system for 1 h at a flow rate of 200 uL/min. Am-
monium formate (1 M) and 0.26 M formic acid in 10%
ACN (mobile phase B) were then used in a linear gradi-
ent. The eluent was monitored by UV absorbance at 280
nm. A total of 10 fractions were collected between 20%
and 60% of mobile phase B gradient, and were lyophi-
lized to dryness.
Each fraction was resuspended in 80 μL of 95% water,
0.1% formic acid, 5% ACN, 0.02% trifluoroacetic acid
(Buffer A) and the digested peptides were purified using
OMIX C18 tips (Varian), eluted using 5 μL of 65% aceto-
nitrile solution (0.1% formic acid, 0.02% trifluoacetic
acid). Samples were loaded on an Agilent 1100 HPLC by
the autosampler onto a 2 cm C18 trap column and the
peptides were eluted onto a resolving 5 cm analytical
C18 column. The samples were loaded at 15 μL/min for
5 min, then the 103 min gradient was run at 400 nL/min
(split from 4 μL/min) starting from 0 to 40% B, followed
by 4 min linear gradient to 65%, and finally to 100% B
for 1 min. The peptides were subjected to nanoelectros-
pray ionization followed by tandem mass spectrometry
(MS/MS) in an LTQ Orbitrap XL (Thermo, Inc.)
coupled online to the HPLC. Data files were created by
the Mascot Daemon (version 2.2) and Extract_MSn, and
the parameters were: 300 Da minimum mass; 4000 Da
maximum mass; automatic precursor charge selection;
10 minimum peaks per MS/MS scan; and 1 minimum
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Fisher Scientific, UK) was used for data acquisition.
Quantitation of proteins by MaxQuant software
Mass spectra were analyzed using MaxQuant software
(version 1.0.0.7), which generates a peak list as well as
SILAC- and extracted ion current-based quantitation for
SILAC pairs. Raw MS files from all replicates were
loaded onto the MaxQuant simultaneously, and identifi-
cation and quantification of individual peptides were
assembled into protein groups. MaxQuant, in conjunc-
tion with Mascot (version 2.2, Matrix Science), executes
spectral search against a concatenated International Pro-
tein Index (IPI) human protein database (version 3.54
containing 39,925 entries) and a decoy database. Para-
meters included: trypsin enzyme specificity, SILAC
double measurements of Lys6 and Arg8, 1 missed cleav-
age, minimum peptide length of 7 amino acids, mini-
mum of 1 unique peptide, top 6 MS/MS peaks per 100
Da, peptide mass tolerance of 20 ppm for precursor ion
and MS/MS tolerance of 0.5 Da. Oxidation of methio-
nine and N-terminal protein acetylation for variable
modifications and cysteine caramidomethylation for
fixed modification. All entries were filtered using a false
positive rate of 1% both at the peptide and protein levels,
and false positives were removed. Quantification via nor-
malized H/L ratios was based on minimum of 3 peptide
ratio counts. Protein group entries with a normalized
ratio significance B score of ≤ 0.05 or significance A
score of ≤ 0.05 were retained for further analysis.
Bioinformatic analysis of amniocyte lysate proteome and
candidate selection
The protein reports from MaxQuant were loaded into
Microsoft Excel. To visualize and assign functional
annotation to over-represented or under-represented
proteins, Ingenuity Pathway Analysis (version 8.0, IPA)
software was used with IPI numbers as entries, generat-
ing a list of canonical pathways that are statistically sig-
nificant by Fisher’s exact test. A Fisher’s exact test
identified canonical pathways most significant to the
dataset. Relevant information and annotations for each
candidate protein were searched from databases includ-
ing UniProt, Human Protein Reference Database and
Entrez Gene. A protein association network was created
where molecules are represented as nodes connected via
edges which represent the supporting evidence. Cluster
analysis was performed using CIMminer (http://discover.
nci.nih.gov/cimminer).
To select candidate proteins that show differential ex-
pression due to T21, we applied a series of filters to the
list. First, we calculated standard deviation from the con-
trol pair (normal to normal ratio) for amniocyte lysate.
Applying the values of two standard deviations (2σ;equivalent to 95.45%) from the mean (μ) to the control
pair, we created a list of proteins that show significant
difference (outside of μ ± 2σ; ~4.55%), and considered
these proteins as the “variable proteins”. Next, we ap-
plied the same 2σ value to the experimental pairs (T21
amniocytes paired with chromosomally normal amnio-
cytes; pairs 1, 2, and 3), and created separate lists of pro-
teins that show significant difference (outside of μ ± 2σ).
We collated these lists together and filtered further by
removing the “variable proteins”, reverse hits and known
contaminants. Also, we excluded the proteins that fail to
show significant p-values (less than 0.05) for either Sig-
nificance A or Significance B calculated by MaxQuant.
“Unknown” or “predicted” proteins were removed. Can-
didates for verification were selected based on the fol-
lowing additional criteria. First, a protein has to be
quantified based on two or more razor peptides and
quantification ratios for all peptides should display
consistency. Secondly, quantification results with the
same pattern of expression should be available for the
protein from two experimental pairs. If the result from
the third experimental pair is available, it should show
similar pattern of expression or not clear differential ex-
pression (defined as H/L ratio within the μ ± 0.5σ).Sample preparation and SRM method development
For verification, we collected ten additional (five T21 and
five CN) amniocyte samples from 15 to 18 weeks of gesta-
tion that have been cultured for cytogenetic analysis.
Amniocytes were harvested using PBS-based Cell Dissoci-
ation Buffer (Gibco) and were gently washed with 1X PBS
buffer to remove any external proteins. After centrifugation
and aspirating the supernatant, cell pellets were frozen until
use. Cell pellets were resuspended with 100 μL of 0.1% Rapi-
Gest SF surfactant (Waters) in 25 mM ammonium bicar-
bonate solution, and were subjected to vortexing and
sonication for 3 × 30 s. Total protein for each amniocyte
lysate sample was measured by the Bradford assay
(Pierce), and the volume was adjusted to extract equal
amounts of total protein from individual samples. Lysate
proteins (20 μg) were denatured with 0.1% RapiGest SF
at 60°C, reduced with 10 mM dithiothreitol, and alkylated
with 20 mM iodoacetamide. Samples were then divided into
two aliquots (10 μg each) and digested with sequencing
grade modified trypsin (Promega) at a trypsin: protein ratio
of 1:30, overnight at 37°C. Ninty six femtomoles of heavy
13C6,
15N2 L-Lysine-labelled peptide (LSEPAELTDAVK*) of
KLK3 protein was added as an internal standard. RapiGest
SF was cleaved with 1% trifluoroacetic acid and samples
were centrifuged at 1500 x g for 10 min to remove precipi-
tates. Peptides were purified and extracted using 10 μL
OMIX C18 tips (Varian), and were eluted using 5 μL of 65%
acetonitrile solution with 0.1% formic acid. The final sample
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injection, so that each sample was analyzed six times.
Peptides were separated on a C18 column-liquid chroma-
tography setup online-coupled to a triple-quadrupole mass
spectrometer (TSQ Vantage, Thermo Scientific) using a
nanoelectrospray ionization source (nano-ESI, Proxeon A/
S). The details of liquid chromatography and MS methods
can be found elsewhere [28]. Briefly, a 60-min, three-step
gradient was used to load peptides onto the column via an
EASY-nLC pump (Proxeon A/S), and peptides were ana-
lyzed by an SRM method using the following parameters:
predicted CE values, 0.002 m/z scan width, 0.05 s scan time,
0.2 Q1, 0.7 Q3, 1.5 mTorr Q2 pressure and tuned tube lens
values.
SRM method development is depicted in Figure 3. We
aimed to identify two unique proteotypic peptides per candi-
date protein that produce strong peaks with minimal
interference. The GPM proteomics database (http://mrm.
thegpm.org) was used to select the top 5 peptides perFigure 3 A schematic representation of SRM method development fo
and development of SRM assay. (A) MS1 spectrum of peptide GDGPVQGIIN
and SILAC-labeled Down syndrome (heavy) amniocytes revealed differentia
GDGPVQGIINFEQK acquired with LTQ-Orbitrap confirmed peptide identity a
SRM for peptide GDGPVQGIINFEQK in the triple quadrupole included 8 y-io
the final SRM assay.protein based on the intensity of +2 ions. The next step was
to confirm their presence from our SILAC proteome results
and/or to confirm in SRM atlas (http://srmatlas.org). Pep-
tides of <7 or >20 amino acids in length were eliminated, as
well as those with significant +3 ion intensities. Peptides
with N-terminal cysteine residues or methionine were
avoided. For proteins with multiple peptides that meet the
aforementioned criteria, only two peptides with the top in-
tensities were retained. The uniqueness of all peptides were
ensured using the Basic Local Alignment Search Tool
(BLAST; https://blast.ncbi.nlm.nih.gov/Blast.cgi). Quantifica-
tion was executed after normalization against a set of ten
peptides of high-abundance housekeeping proteins to offset
technical variations.
Analysis of SRM data
Raw files for each sample were analyzed using Pinpoint
software (v 1.0) to extract areas under the curve for pro-
tein quantification. The statistical software R was usedr candidates and controls. Differential expression of SOD1 protein
FEQK in the equimolar mixture of digested lysates of normal (light)
l expression of SOD1 protein. MS/MS spectrum of peptide
nd showed relative intensity of y- and b-fragment ions. (B) Survey
n transitions, and the three most intense transitions were chosen for
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areas and subsequent analysis. The first replicate and in-
jection for each sample served as a reference to which
the subsequent replicates of the same sample were nor-
malized. A normalization constant was computed by
constructing a linear model that was fitted using an M-
estimator and robust regression. Normalized values
(based on the log2-transformed peak areas) for peptide
abundance were used to calculate the protein abundance
ratio for biological replicates. CVs were computed based
on normalized peptide area.
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